Rapid Screening of Antimicrobial Synthetic Peptides

Jaśkiewicz, Maciej; Orłowska, Małgorzata; Olizarowicz, Gabriela; Migoń, Dorian; Grzywacz, Daria; Kamysz, Wojciech

doi:10.1007/s10989-015-9494-4

Cited by 19 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The plates were visualized under UV light. The bioautography was performed on a developed TLC plate 80 . S.aureus ATCC 29213 was employed as a test organism.…”

Section: Methodsmentioning

confidence: 99%

Isolation, characterization, anti-MRSA evaluation, and in-silico multi-target anti-microbial validations of actinomycin X2 and actinomycin D produced by novel Streptomyces smyrnaeus UKAQ_23

Qureshi

Bholay

Pankaj

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Streptomyces smyrnaeus UKAQ_23, isolated from the mangrove-sediment, collected from Jubail,Saudi Arabia, exhibited substantial antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA), including non-MRSA Gram-positive test bacteria. The novel isolate, under laboratory-scale conditions, produced the highest yield (561.3 ± 0.3 mg/kg fermented agar) of antimicrobial compounds in modified ISP-4 agar at pH 6.5, temperature 35 °C, inoculum 5% v/w, agar 1.5% w/v, and an incubation period of 7 days. The two major compounds, K1 and K2, were isolated from fermented medium and identified as Actinomycin X2 and Actinomycin D, respectively, based on their structural analysis. The antimicrobial screening showed that Actinomycin X2 had the highest antimicrobial activity compared to Actinomycin D, and the actinomycins-mixture (X2:D, 1:1, w/w) against MRSA and non-MRSA Gram-positive test bacteria, at 5 µg/disc concentrations. The MIC of Actinomycin X2 ranged from 1.56–12.5 µg/ml for non-MRSA and 3.125–12.5 µg/ml for MRSA test bacteria. An in-silico molecular docking demonstrated isoleucyl tRNA synthetase as the most-favored antimicrobial protein target for both actinomycins, X2 and D, while the penicillin-binding protein-1a, was the least-favorable target-protein. In conclusion, Streptomyces smyrnaeus UKAQ_23 emerged as a promising source of Actinomycin X2 with the potential to be scaled up for industrial production, which could benefit the pharmaceutical industry.

show abstract

“…The plates were visualized under UV light. The bioautography was performed on a developed TLC plate 80 . S.aureus ATCC 29213 was employed as a test organism.…”

Section: Methodsmentioning

confidence: 99%

Isolation, characterization, anti-MRSA evaluation, and in-silico multi-target anti-microbial validations of actinomycin X2 and actinomycin D produced by novel Streptomyces smyrnaeus UKAQ_23

Qureshi

Bholay

Pankaj

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…NMR spectra were collected with 32 transients and 512 points in the indirect dimension. NOESY spectra were collected with mixing times of 100 ms and 200 ms. Inter-strand NOEs were identified using a 3D X-filtered experiment with a mixing time of 120 ms and a 50/50 mixture of unlabeled peptide and a peptide uniformly 13 C, 15 N labeled at Leu2 [53]. Initial models of the AMPs were generated from Hα chemical shifts using the CS-Rosetta webserver at the BMRB [54].…”

Section: Nmr Structure Determinationmentioning

confidence: 99%

“…Cit 1.1 has shown intriguing activity against Gram-positive and Gramnegative species including: Staphylococcus aureus, Staphylococcus epidermis, Enterococcus faecalis, Escherichia coli, and Klebsiella pneumonia [12]. Conversely, studies evaluated the antifungical activity of Cit 1.1 against Candida species using direct bioautography [13] and against Candida albicans, Candida tropicalis and Candida krusei isolated from patients with [15]. Tyler and co-workers suggested that the α-helical conformation of Cit 1.1 was critical to antimicrobial activity [16].…”

Section: Introductionmentioning

confidence: 99%

Understanding interactions of Citropin 1.1 analogues with model membranes and their influence on biological activity

et al. 2019

View full text Add to dashboard Cite

The rapid emergence of resistant bacterial strains has made the search for new antibacterial agents an endeavor of paramount importance. Cationic antimicrobial peptides (AMPs) have the ability to kill resistant pathogens while diminishing the development of resistance. Citropin 1.1 (Cit 1.1) is an AMP effective against a broad range of pathogens. 20 analogues of Cit 1.1 were prepared to understand how sequence variations lead to changes in structure and biological activity. Various analogues exhibited an increased antimicrobial activity relative to Cit 1.1. The two most promising, AMP-016 (W3F) and AMP-017 (W3F, D4R, K7R) presented a 2-to 8-fold increase in activity against MRSA (both = 4 μg/mL). AMP-017 was active against E. coli (4 μg/mL), K. pneumoniae (8 μg/mL), and A. baumannii (2 μg/mL). NMR studies indicated that Cit 1.1 and its analogues form a head-to-tail helical dimer in a membrane environment, which differs from a prior study by Sikorska et al. Active peptides displayed a greater tendency to form α-helices and to dimerize when in contact with a negatively-charged membrane. Antimicrobial activity was observed to correlate to the overall stability of the α-helix and to a positively charged N-terminus. Biologically active AMPs were shown by SEM and flow cytometry to disrupt membranes in both Gram-positive and Gram-negative bacteria through a proposed carpet mechanism. Notably, active peptides exhibited typical serum stabilities and a good selectivity for bacterial cells over *

show abstract

“…Despite their great potential, active antifungal compounds can be extracted from natural sources in small amount that is not sufficient to carry out microbiological tests and makes the process unprofitable [ 174 ]. However, many natural antifungal peptides represent excellent starting points for future therapeutic agents.…”

Section: Antifungal Peptidesmentioning

confidence: 99%

Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds

Bondaryk

Staniszewska

Zielińska

et al. 2017

JoF

100

View full text Add to dashboard Cite

Invasive fungal infections are associated with high mortality rates, despite appropriate antifungal therapy. Limited therapeutic options, resistance development and the high mortality of invasive fungal infections brought about more concern triggering the search for new compounds capable of interfering with fungal viability and virulence. In this context, peptides gained attention as promising candidates for the antimycotics development. Variety of structural and functional characteristics identified for various natural antifungal peptides makes them excellent starting points for design novel drug candidates. Current review provides a brief overview of natural and synthetic antifungal peptides.

show abstract

Rapid Screening of Antimicrobial Synthetic Peptides

Cited by 19 publications

References 31 publications

Isolation, characterization, anti-MRSA evaluation, and in-silico multi-target anti-microbial validations of actinomycin X2 and actinomycin D produced by novel Streptomyces smyrnaeus UKAQ_23

Isolation, characterization, anti-MRSA evaluation, and in-silico multi-target anti-microbial validations of actinomycin X2 and actinomycin D produced by novel Streptomyces smyrnaeus UKAQ_23

Understanding interactions of Citropin 1.1 analogues with model membranes and their influence on biological activity

Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds

Contact Info

Product

Resources

About